A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM | MicrobiomeTrials← Back to trialsNCT04622046
A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM
CompletedPHASE3INTERVENTIONAL
Trial Details
Start: 2020-11-13Est. Completion: 2023-11-08
Enrollment target: 25 participants Locations- Research Site, Bunkyō City, Japan
- Research Site, Fukuoka, Japan
- Research Site, Kumamoto, Japan
- Research Site, Kurume-shi, Japan
- Research Site, Matsumoto-shi, Japan
- Research Site, Nagoya, Japan
- Research Site, Nankoku-shi, Japan
- Research Site, Sagamihara-shi, Japan
- Research Site, Sapporo, Japan
- Research Site, Shinjuku-ku, Japan
- Research Site, Suita-shi, Japan
Other microbiome trials you might be interested in
Amyloidosis, Hereditary
The study design is a prospective registry including asymptomatic and symptomatic patients who carry a pathogenic TTR mu…
Richmond, United StatesEst. completion Dec 1, 2030
ATTR Amyloidosis Wild Type
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-typ…
Aarhus, DenmarkEst. completion Jul 2026